BNTX) has been getting increased investor attention due to its work on vaccine development against the novel coronavirus. So far in the year, BNTX stock has almost doubled. Let’s take a closer look at what investors may expect from the shares of the Mainz, Germany-headquartered firm in the next three-plus months.” data-reactid=”12″>BioNTech (NASDAQ:BNTX) has been getting increased investor attention due to its work on vaccine development against the novel coronavirus. So far in the year, BNTX stock has almost doubled. Let’s take a closer look at what investors may expect from the shares of the Mainz, Germany-headquartered firm in the next three-plus months.
Source: Shutterstock
COVID-19 infections is close to 30 million. The outbreak has already killed almost 1 million people worldwide. Therefore, global citizens and governments would like to welcome the news that a potential cure against the disease is ready for commercialization. Billions of people throughout the world would eventually need to be inoculated against the virus.
messenger ribonucleic acid (mRNA) vaccine development. Messenger RNA transmits instructions to the body to produce proteins against a given disease. BioNTech was relatively unknown in the public eye before the Covid-19 pandemic.
InvestorPlace – Stock Market News, Stock Advice & Trading Tips” data-reactid=”27″>InvestorPlace – Stock Market News, Stock Advice & Trading Tips
BNTX Stock Gets Boost from UK Pact
Pfizer (NYSE:PFE) to develop a vaccine. Earlier in July, the U.K government signed an agreement with the two companies to purchase 30 million doses of the potential mRNA vaccine. BNTX stock jumped more than 13% in the two days following that July 20 announcement.” data-reactid=”29″>The biotechnology company has recently been partnering with Pfizer (NYSE:PFE) to develop a vaccine. Earlier in July, the U.K government signed an agreement with the two companies to purchase 30 million doses of the potential mRNA vaccine. BNTX stock jumped more than 13% in the two days following that July 20 announcement.
announced, “they have submitted an amended protocol to the U.S. Food and Drug Administration to expand the enrollment of their Phase 3 pivotal COVID-19 vaccine trial to up to approximately 44,000 participants.”
CVAX), money to continue their work against the disease. The company thus has plenty of cash at hand.” data-reactid=”31″>Over the course of the year, the German government has awarded BioNTech, as well as CureVac (NASDAQ:CVAX), money to continue their work against the disease. The company thus has plenty of cash at hand.
Ebb and Flow of Investor Euphoria
The 52-week range of BNTX stock has been $12.53 (Oct. 14, 2019) – $105 (March 18, 2020). In other words, as many stocks worldwide were hitting 52-week low in mid-March, BioNTech investors were jubilant.
Yet in a matter of weeks, the shares were down to the $40 level. After range-trading between $40 and $50 until late June, BNTX stock made another fast move up to go over $100 in late July on the strength of that UK news. Now the shares are hovering around $67.
COVID-19 Vaccine Maker Pledge, which says
“We, the undersigned biopharmaceutical companies, want to make clear our ongoing commitment to developing and testing potential vaccines for COVID-19 in accordance with high ethical standards and sound scientific principles.”
U.K.’s Vaccine Taskforce, has recently said,
“The fact that we have so many promising candidates already shows the unprecedented pace at which we are moving. But I urge against being complacent or overoptimistic. The fact remains we may never get a vaccine and, if we do get one, we have to be prepared that it may not be a vaccine which prevents getting the virus, but rather one that reduces symptoms.”
Joint efforts by BioNTech and Pfizer may come to successful fruition in the coming months, which could possibly push the share price of both BNTX stock and PFE stock to new highs. However, any delays in the process could also mean declines in either stock, especially in BioNTech, as the shares are volatile.
After all, biopharma investing comes with high risks and returns. For now, much of the news might be already priced into BNTX stock. Until there is the hope of regulatory approval, the shares may not be able to make new highs.
CNCR), ETFMG Treatments, Testing and Advancements ETF (NYSEARCA:GERM), and Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC).” data-reactid=”50″>Those investors who would like exposure to BNTX stock, but are not ready to commit capital fully to the shares may also consider buying an exchange-traded fund (ETF). Examples would include Loncar Cancer Immunotherapy ETF (NASDAQ:CNCR), ETFMG Treatments, Testing and Advancements ETF (NYSEARCA:GERM), and Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC).
educational articles on long-term investing.
More From InvestorPlace
BioNTech Investor Fortunes Rise and Fall on Headlines, Pacts and Funding appeared first on InvestorPlace.” data-reactid=”59″>The post BioNTech Investor Fortunes Rise and Fall on Headlines, Pacts and Funding appeared first on InvestorPlace.
